Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H2P0
UPID:
ADNP_HUMAN
Alternative names:
Activity-dependent neuroprotective protein
Alternative UPACC:
Q9H2P0; E1P5Y2; O94881; Q5BKU2; Q9UG34
Background:
The Activity-dependent neuroprotector homeobox protein, with alternative names such as Activity-dependent neuroprotective protein, plays a crucial role in transcriptional regulation and neuroprotection. It enhances WNT-beta-catenin signaling, crucial for neural induction and differentiation, and may contribute to erythroid differentiation.
Therapeutic significance:
Linked to Helsmoortel-van der Aa syndrome, characterized by intellectual disability and autism spectrum disorder, this protein's understanding could pave the way for innovative treatments targeting neurodevelopmental disorders.